Journal of the American College of Surgeons
-
Although sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been shown to improve cardiovascular outcomes in general, little is presently known about any sex-specific changes that may result from this therapy. We sought to investigate and quantify potential sex-specific changes seen with the SGLT-2 inhibitor canagliflozin (CAN) in a swine model of chronic myocardial ischemia. ⋯ Males treated with CAN had significant improvements in cardiac function that were not observed in females. Moreover, CAN treatment in males was associated with significantly more changes in protein expression than in females. The increased proteomic changes seen in the male CAN group likely contributed to the more robust changes in cardiac function seen in males treated with CAN.